Additional details around the FirstSight blood test in detecting precancerous colorectal adenomas were released at 2020 Virtual @ASCO, highlighting a significant association between blood test scores and polyps found in enrolled subjects by colonoscopy. https://t.co/W9MYTJg5cC
We are excited to share #positivedata from our U.S. study evaluating the efficacy of our FirstSight blood test in detecting colorectal adenomas and #cancer.
Access the full presentation released by Digestive Disease Week (DDW) here: https://t.co/WuoVy42UqP!
Thanks for visiting us at #DDW19 to learn about the #CellMaxLife blood test for Adenoma detection. Partner with us to make #colorectalcancer a preventable disease.
#CellMaxLife has developed the first blood test for adenoma detection that enables more diagnostic colonoscopies. Come by our Booth #4430 at #DDW19 to find out more.
Are you curious to learn about the blood test for Adenoma detection? Come by our Booth #4430 at #DDW19 to find out more about our FirstSight Blood Test.
Great audience engagement on #liquidbiopsy for precancer and early colorectal cancer at The Personalized Medicine World Congress #pmwc19#stanfordmedicine
@FierceBiotech on our cell-based #liquidbiospy for precancer and colorectal cancer. Podium presentation at @ASCO's GI meeting. #GI19
https://t.co/ET5xelCfhd
#Motleyfool on the potential of #CellMaxLife to "dethrone" non-invasive colorectal #cancerscreening incumbents with a simple blood test ....
https://t.co/xJSWcU5N90
Thanks for visiting us at booth #804 at #AMP2018 to learn about the #CellMaxLife blood testing platform for pre-cancer and colorectal #cancer. Partner with us to make #colorectalcancer a preventable disease.
#CellMax's proprietory platform detects pre-cancerous adenomas before they become #colorectalcancer, using 1 tube of blood. Come by Booth #804 at #AMP2018 to learn about the platform that has been awarded 16 patents and was showcased on the #ASCO18 Podium!
LISTEN: @HealthProRadio on the #CellMax blood test- the 1st and only blood test for pre-cancer detection enabling #colorectalcancer prevention. https://t.co/GelZ4zFjSK
Our founder and CEO, Atul Sharan, is speaking @PMWCintl about CellMax Life's CTC blood test. #CellMaxCTC has demonstrated a high sensitivity for early cancer detection, unlike cfDNA and methylation-based methods that have demonstrated limited sensitivity for this purpose #PMWC18
For CTC testing CellMax has an innovative platform. Their PD-L1 data in CTCs correlates well with tissue PD-L1 by IHC. (AACR18-Hsieh) gives genomics as well.
Insightful article written by @biotechvisigoth at @MedCityNews, highlighting 6 new U.S. patents granted for our globally affordable and non-invasive #CellMaxCTC blood test to detect #colorectalcancer at its earliest stages: https://t.co/k3xgBgjTW8
We are proud to announce 6 U.S. patents for our affordable #CellMaxCTC blood test for early detection and monitoring of cancer with an accuracy of 84 to 88% for colorectal cancer detection. https://t.co/AGgEqR5qOJ
Our ultra-sensitive CTC platform was granted 6 US patents. @Stanford Chief of Gastroenterology Shai Friedland sees potential for the platform to be the first line early colorectal cancer detection test for 100 million Americans eligible for screening. https://t.co/AGgEqR5qOJ